Mantle Cell Lymphoma Care From Diagnosis Through Relapse: Expert Guidance on Applying the Latest Evidence

Download All
Explore key issues in the management of MCL in this comprehensive program designed to keep you abreast of rapidly evolving treatment strategies. Gain insights on new developments as they emerge with the interactive module, downloadable slideset, short expert commentaries, and an Interactive Decision Support Tool that lets you compare your treatment choices for MCL patient scenarios you enter with those of 5 experts.
Stephen Ansell, MD, PhD
Christopher R. Flowers, MD, MS
Julie M. Vose, MD, MBA

ClinicalThought: MCL Management

Induction therapy in mantle cell lymphoma is rapidly evolving. How do you treat your patients with MCL?

Julie M. Vose, MD, MBA Released: April 30, 2018

Ibrutinib and acalabrutinib are both active in relapsed MCL. Read how I consider safety, long-term data, and patient preferences when deciding between these BTK inhibitors.

Christopher R. Flowers, MD, MS Released: August 10, 2018

Module

Review practical guidance and the most recent data in this expert analysis of challenging MCL cases, including discussions on when to initiate therapy, how to select optimal first-line treatment, and what to do at progression.

Stephen Ansell, MD, PhD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: November 13, 2018 Expired: No longer available for credit

Downloadable Slideset

Download the slides from our online module to review expert guidance and recent for management of patients with MCL, including when to initiate therapy and how to select optimal treatment for individual patients.

Stephen Ansell, MD, PhD Released: November 13, 2018
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
AbbVie
AstraZeneca Pharmaceuticals
Pharmacyclics Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings